A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
A phase 3 trial of Trastuzumab pamirtecan, Doxorubicin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by BioNTech SE, now recruiting.
Overview
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer is a phase 3 interventional study registered as NCT06340568 by BioNTech SE, with 480 participants planned, started 2025-06-10 and due to reach its primary completion in 2028-03. Interventions recorded: BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialStudy of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Shares Trastuzumab pamirtecan, BioNTech.
- TrialA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Shares Trastuzumab pamirtecan, BioNTech.
- TrialPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialStudy of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan
Shares Docetaxel, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialDESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC
Shares Docetaxel, Paclitaxel / nab-paclitaxel, Endometrial cancer.